Trial · NCT05111626
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
NCT05111626, Phase 3, Terminated, Amgen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. Trials, record NCT05111626. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05111626
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- NCT number
- NCT05111626
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 515 participants, actual
- Lead sponsor
- Amgen
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Bemarituzumab, Nivolumab, Chemotherapy, Placebo
- First posted
- 2021-11-08
- Last updated
- 2026-09-10
Source ClinicalTrials.gov
Registered outcomes40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Number of Participants Who Experienced DLTs | 28 days | |
| Primary | Part 1: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAEs) | Up to 4.5 years | |
| Primary | Part 1: Number of Participants Who Experienced One or More Related TEAEs | Up to 4.5 years | |
| Primary | Part 1: Number of Participants With Clinically Significant Changes in Vital Signs | Up to 4.5 years | |
| Primary | Part 1: Number of Participants With Clinically Significant Changes in Visual Acuity | Up to 4.5 years | |
| Primary | Part 1: Number of Participants With Clinically Significant Changes in Physical Examinations | Up to 4.5 years | |
| Primary | Part 1: Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests | Up to 4.5 years | |
| Primary | Part 2: Overall Survival in FGFR2b ≥ 10% 2+/3+ Tumor Cell Staining Participants | Up to 4.5 years | |
| Secondary | Part 1: Objective Response (OR) | Up to 4.5 years | |
| Secondary | Part 1: Duration of Response (DoR) | Up to 4.5 years |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05111626
GET https://conductscience.org/api/trials/v1/NCT05111626/registered?page=2